It was around this time two years ago that the media was all abuzz about a libido nasal spray, a drug that would treat erectile dysfunction (ED) easily and discretely, just like you treat a stuffy nose. It seemed so futuristic and cool. It also seemed to be much ado about nothing given that the research hadn’t even begun (which didn’t stop media outlets from running story after story about it).

Associated Press reported yesterday that the companies' developing the drug, and the equally important novel delivery method, are delaying further study after the FDA raised “serious concerns” particularly regarding increases in blood pressure. The article continues:

In addition to higher blood pressure, previous trials showed negative effects for bremelanotide included nausea, vomiting, flushing, headache, spontaneous erection and nasal symptoms.

The drug is also in mid-stage testing as a treatment for female sexual dysfunction.

I guess its a sign of progress when companies strive to make drugs that are equally ineffective for men and women.

In case anyone was wondering about the real point of any drug development, the article highlights the fact that the company’s stock price dropped 63% following the announcement.

Read more – Forbes.com: Out of the Gate: King and Palatin Drop

_{Photo Credit: David Buffington/Getty Images}